Omixon is entering the field of post-transplant monitoring. To ensure its position in the market our company has entered a strategic partnership with Organ Monitoring Group (OMG) founded by Doug Bost to bring our newest product, HoloGRAFT, to market.
Doug Bost joined Omixon in the position of VP of Transplant Monitoring and in practice he covers the following activities: product manager of HoloGRAFT, coordination of the development, the manufacturing and quality controls of HoloGRAFT and supports market launch.
In the meantime, he joined Omixon in April 2022, Doug Bost also became a member of the Scientific Advisory Board for Digital PCR at QIAGEN GmbH. In his role on the SAB, Doug will assist QIAGEN in the assessment of its core technologies and R&D programs, drive R&D related organizational learning by challenging projects, provide scientific advice to the Executive Board, and systematically enable access to leading experts and opinion leaders.
Congratulations to Doug!